Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies
Crossref DOI link: https://doi.org/10.1007/s10096-016-2576-1
Published Online: 2016-02-06
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Marotta, P.
Bailey, R.
Elkashab, M.
Farley, J.
Feinman, S. V.
Peltekian, K.
Poliquin, M.
Witt-Sullivan, H.
Rampakakis, E.
Drolet, M.
Cooper, C.
Funding for this research was provided by:
Merck Canada Inc.
License valid from 2016-02-06